<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074048</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000341680</org_study_id>
    <secondary_id>NCI-04-C-0014</secondary_id>
    <secondary_id>NCI-6048</secondary_id>
    <nct_id>NCT00074048</nct_id>
    <nct_alias>NCT00071318</nct_alias>
  </id_info>
  <brief_title>BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia</brief_title>
  <official_title>Phase II Trial Of BL22 Immunotoxin In Hairy Cell Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal&#xD;
      cells. This may be an effective treatment for hairy cell leukemia that has not responded to&#xD;
      treatment with cladribine.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying BL22 immunotoxin to see how well it works in&#xD;
      treating patients previously treated with cladribine for hairy cell leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in patients with cladribine-resistant hairy cell leukemia&#xD;
           treated with BL22 immunotoxin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response duration in patients treated with this drug.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Correlate BL22 blood levels and toxicity of this drug with the development of&#xD;
           neutralizing antibodies in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 followed by&#xD;
      rest.&#xD;
&#xD;
      Patients are then evaluated at 8 weeks. Patients achieving complete hematologic remission are&#xD;
      followed. All other patients continue to receive BL22 immunotoxin as above on days 1, 3, and&#xD;
      5. Treatment repeats every 4 weeks for up to a total of 16 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients achieving CR without minimal residual disease&#xD;
      (MRD) receive 2 courses beyond CR. Patients achieving CR with MRD receive 4 courses beyond&#xD;
      CR.&#xD;
&#xD;
      Patients are followed every 4 months for 1 year, every 6 months for 1 year, and then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>After even cycle numbers (2,4,6,8,10)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response: [Timeframe: Date that a response begins with the date that PD is documented.]</measure>
    <time_frame>30 days after last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BL22 immunotoxin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BL22</intervention_name>
    <description>Dosing via IV on Days 1,3, and 5.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed hairy cell leukemia&#xD;
&#xD;
          -  CD22-positive disease by fluorescence-activated cell sorting with anti-CD22 antibody&#xD;
&#xD;
          -  Meets at least 1 of the following indications for treatment:&#xD;
&#xD;
               -  Absolute neutrophil count less than 1,000/mm^3&#xD;
&#xD;
               -  Hemoglobin less than 10 g/dL&#xD;
&#xD;
               -  Platelet count less than 100,000/mm^3&#xD;
&#xD;
               -  Absolute lymphocyte count greater than 20,000/mm^3&#xD;
&#xD;
               -  Symptomatic splenomegaly&#xD;
&#xD;
          -  Meets 1 of the following response criteria:&#xD;
&#xD;
               -  No response&#xD;
&#xD;
               -  Complete response (CR) or partial response (PR) less than 2 years in duration&#xD;
                  after the last course of prior cladribine&#xD;
&#xD;
               -  CR or PR less than 4 years in duration after a second or later course of prior&#xD;
                  cladribine&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin no greater than 2.2 mg/dL&#xD;
&#xD;
          -  Albumin at least 3.0 g/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.4 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No serum that neutralizes more than 75% of the activity of 1 Âµg/mL of BL22 immunotoxin&#xD;
             using a bioassay&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other concurrent uncontrolled illness that would preclude study participation&#xD;
&#xD;
          -  Understand and give informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior BL22 immunotoxin&#xD;
&#xD;
          -  More than 12 weeks since prior monoclonal antibody therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior systemic cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior systemic steroids (except stable doses of prednisone no&#xD;
             greater than 20 mg/day)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Kreitman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>June 17, 2010</last_update_submitted>
  <last_update_submitted_qc>June 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Radhika Parikh</name_title>
    <organization>MedImmune Inc.</organization>
  </responsible_party>
  <keyword>refractory hairy cell leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

